RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/34391065http://www.w3.org/2000/01/rdf-schema#comment"Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown a high response rate and long progression-free survival in primary treatment of ALK-positive non-small-cell lung cancer (NSCLC). De novo resistance or refractory subtype is rare event. Herein, we identify the first case with serial next-generation sequencing (NGS) results that harboured a rare echinoderm microtubule associated protein like 4 gene (EML4) -ALK (breaking site at exon 19) fusion in a lung adenocarcinoma (LUAD) patient who acquired alectinib resistance rapidly (less than 3 months), followed by multi-drug resistance and short survival time."xsd:string
http://purl.uniprot.org/citations/34391065http://purl.org/dc/terms/identifier"doi:10.1016/j.lungcan.2021.07.020"xsd:string
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/author"Fan M."xsd:string
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/author"Liu D."xsd:string
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/author"Zhang C."xsd:string
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/author"Xu X."xsd:string
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/author"Wen J."xsd:string
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/date"2021"xsd:gYear
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/name"Lung Cancer"xsd:string
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/pages"32-35"xsd:string
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/title"Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance."xsd:string
http://purl.uniprot.org/citations/34391065http://purl.uniprot.org/core/volume"160"xsd:string
http://purl.uniprot.org/citations/34391065http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/34391065
http://purl.uniprot.org/citations/34391065http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/34391065
http://purl.uniprot.org/uniprot/#_A0A0K2YUJ3-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065
http://purl.uniprot.org/uniprot/#_D1MAM4-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065
http://purl.uniprot.org/uniprot/#_D1MAM5-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065
http://purl.uniprot.org/uniprot/#_B4DIT9-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065
http://purl.uniprot.org/uniprot/#_B2MXD7-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065
http://purl.uniprot.org/uniprot/#_B2MXD8-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065
http://purl.uniprot.org/uniprot/#_B2MXD9-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065
http://purl.uniprot.org/uniprot/#_B2MXE0-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065
http://purl.uniprot.org/uniprot/#_B2MXE1-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065
http://purl.uniprot.org/uniprot/#_B2MXE2-mappedCitation-34391065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34391065